126 related articles for article (PubMed ID: 9396163)
1. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4'-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanil ide derivatives.
Matsuhisa A; Tanaka A; Kikuchi K; Shimada Y; Yatsu T; Yanagisawa I
Chem Pharm Bull (Tokyo); 1997 Nov; 45(11):1870-4. PubMed ID: 9396163
[TBL] [Abstract][Full Text] [Related]
2. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4-(1,4,5,6-tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)benzanili de derivatives and 4'-(5,6-dihydro-4H-thiazolo[5,4-d][1]benzoazepine-6-carbonyl)benzanilid e derivatives.
Matsuhisa A; Taniguchi N; Koshio H; Yatsu T; Tanaka A
Chem Pharm Bull (Tokyo); 2000 Jan; 48(1):21-31. PubMed ID: 10705470
[TBL] [Abstract][Full Text] [Related]
3. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4'-[5-(substituted methylidene)-2,3,4,5-tetrahydro-1H-1-ben zoazepine-1-carbonyl]benzanilide and 4'-[5-(substituted methyl)-2,3-dihydro-1H-1-benzoazepine-1- carbonyl]benzanilide derivatives.
Matsuhisa A; Kikuchi K; Sakamoto K; Yatsu T; Tanaka A
Chem Pharm Bull (Tokyo); 1999 Mar; 47(3):329-39. PubMed ID: 10212383
[TBL] [Abstract][Full Text] [Related]
4. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4'-(2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-1-carbonyl) benzanilide derivatives.
Matsuhisa A; Koshio H; Sakamoto K; Taniguchi N; Yatsu T; Tanaka A
Chem Pharm Bull (Tokyo); 1998 Oct; 46(10):1566-79. PubMed ID: 9810694
[TBL] [Abstract][Full Text] [Related]
5. Preparation of non-peptide, highly potent and selective antagonists of arginine vasopressin V1A receptor by introduction of alkoxy groups.
Shimada Y; Taniguchi N; Matsuhisa A; Yatsu T; Tahara A; Tanaka A
Chem Pharm Bull (Tokyo); 2003 Sep; 51(9):1075-80. PubMed ID: 12951451
[TBL] [Abstract][Full Text] [Related]
6. Highly potent and orally active non-peptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4'-[(4,4-difluoro-5-methylidene-2,3,4,5-tetrahydro-1H-1-benzoazepin-1-y l)carbonyl]-2-phenylbenzanilide derivatives.
Shimada Y; Taniguchi N; Matsuhisa A; Sakamoto K; Yatsu T; Tanaka A
Chem Pharm Bull (Tokyo); 2000 Nov; 48(11):1644-51. PubMed ID: 11086891
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist.
Tahara A; Saito M; Sugimoto T; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
Naunyn Schmiedebergs Arch Pharmacol; 1998 Jan; 357(1):63-9. PubMed ID: 9459574
[TBL] [Abstract][Full Text] [Related]
8. Preparation of highly potent and selective non-peptide antagonists of the arginine vasopressin V1A receptor by introduction of a 2-ethyl-1H-1-imidazolyl group.
Shimada Y; Akane H; Taniguchi N; Matsuhisa A; Kawano N; Kikuchi K; Yatsu T; Tahara A; Tomura Y; Kusayama T; Wada K; Tsukada J; Tsunoda T; Tanaka A
Chem Pharm Bull (Tokyo); 2005 Jul; 53(7):764-9. PubMed ID: 15997131
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor.
Shimada Y; Taniguchi N; Matsuhisa A; Akane H; Kawano N; Suzuki T; Tobe T; Kakefuda A; Yatsu T; Tahara A; Tomura Y; Kusayama T; Wada K; Tsukada J; Orita M; Tsunoda T; Tanaka A
Bioorg Med Chem; 2006 Mar; 14(6):1827-37. PubMed ID: 16290163
[TBL] [Abstract][Full Text] [Related]
10. 7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist.
Kondo K; Ogawa H; Yamashita H; Miyamoto H; Tanaka M; Nakaya K; Kitano K; Yamamura Y; Nakamura S; Onogawa T; Mori T; Tominaga M
Bioorg Med Chem; 1999 Aug; 7(8):1743-54. PubMed ID: 10482466
[TBL] [Abstract][Full Text] [Related]
11. Differentiation of arginine vasopressin antagonistic effects by selective V2 versus dual V2/V1a receptor blockade in a preclinical heart failure model.
Mondritzki T; Kolkhof P; Sabbah HN; Gheorghiade M; Fürstner C; Schmeck C; Siedentop H; Schaefer S; Truebel H
Am J Ther; 2011 Jan; 18(1):31-7. PubMed ID: 21192248
[TBL] [Abstract][Full Text] [Related]
12. Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds.
Ogawa H; Yamashita H; Kondo K; Yamamura Y; Miyamoto H; Kan K; Kitano K; Tanaka M; Nakaya K; Nakamura S; Mori T; Tominaga M; Yabuuchi Y
J Med Chem; 1996 Aug; 39(18):3547-55. PubMed ID: 8784453
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological profile of VP-343, a novel selective vasopressin V2 receptor antagonist, in rats.
Naito A; Ohtake Y; Hasegaw H; Fukaya AY; Kurasawa T; Naito K; Matsukawa H; Oguma T; Ezure Y; Tsuriya Y; Tanaka H; Koike K; Shigenobu K
Biol Pharm Bull; 2000 Feb; 23(2):182-9. PubMed ID: 10706381
[TBL] [Abstract][Full Text] [Related]
14. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo.
Tahara A; Tomura Y; Wada KI; Kusayama T; Tsukada J; Takanashi M; Yatsu T; Uchida W; Tanaka A
J Pharmacol Exp Ther; 1997 Jul; 282(1):301-8. PubMed ID: 9223568
[TBL] [Abstract][Full Text] [Related]
16. Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.
Serradeil-Le Gal C; Wagnon J; Simiand J; Griebel G; Lacour C; Guillon G; Barberis C; Brossard G; Soubrié P; Nisato D; Pascal M; Pruss R; Scatton B; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 2002 Mar; 300(3):1122-30. PubMed ID: 11861823
[TBL] [Abstract][Full Text] [Related]
17. [Arg8]vasopressin-induced responses of the human isolated coronary artery: effects of non-peptide receptor antagonists.
Bax WA; Van der Graaf PH; Stam WB; Bos E; Nisato D; Saxena PR
Eur J Pharmacol; 1995 Oct; 285(2):199-202. PubMed ID: 8566139
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs.
Yatsu T; Tomura Y; Tahara A; Wada K; Tsukada J; Uchida W; Tanaka A; Takenaka T
Eur J Pharmacol; 1997 Feb; 321(2):225-30. PubMed ID: 9063692
[TBL] [Abstract][Full Text] [Related]
19. Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors.
Tahara A; Tsukada J; Tomura Y; Kusayama T; Wada K; Ishii N; Taniguchi N; Suzuki T; Yatsu T; Uchida W; Shibasaki M
Pharmacol Res; 2005 Mar; 51(3):275-81. PubMed ID: 15661579
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V(1A) receptor.
Kakefuda A; Suzuki T; Tobe T; Tsukada J; Tahara A; Sakamoto S; Tsukamoto S
J Med Chem; 2002 Jun; 45(12):2589-98. PubMed ID: 12036368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]